149 related articles for article (PubMed ID: 33587372)
1. Mohs Micrographic Surgery for the Treatment of Melanoma: A Cross-Sectional Survey on the Barriers, Prevalence, and Practice.
Orfaly VE; Hagstrom EL; Leitenberger JJ; Latour E; Bar A
Dermatol Surg; 2021 Aug; 47(8):1114-1115. PubMed ID: 33587372
[No Abstract] [Full Text] [Related]
2. Practice habits of Mohs surgeons treating melanoma with Mohs surgery: A cross-sectional survey.
Siscos SM; Neill BC; Seger EW; Rajpara A; Hocker TLH
J Am Acad Dermatol; 2021 Mar; 84(3):833-835. PubMed ID: 33022309
[No Abstract] [Full Text] [Related]
3. The Current State of Mohs Surgery for the Treatment of Melanoma: A Nationwide Cross-Sectional Survey of Mohs Surgeons.
Siscos SM; Neill BC; Seger EW; Hooton TA; Hocker TLH
Dermatol Surg; 2020 Oct; 46(10):1267-1271. PubMed ID: 32740213
[TBL] [Abstract][Full Text] [Related]
4. Utilization Patterns of Fellowship-Trained Mohs Surgeons in the Treatment of Melanoma in Situ and Melanoma.
Barklund JS; Cameron MC; Mirhossaini RB; Brown M
Dermatol Surg; 2021 Jun; 47(6):814-815. PubMed ID: 32932262
[No Abstract] [Full Text] [Related]
5. Factors Deterring the Utilization of Mohs Surgery for Treatment of Melanoma: A Nationwide Cross-Sectional Survey of Mohs Surgeons.
Siscos SM; Neill BC; Seger EW; Hocker TLH
Dermatol Surg; 2021 May; 47(5):709-710. PubMed ID: 33905398
[No Abstract] [Full Text] [Related]
6. A national survey of Mohs micrographic surgery in the U.K.
Mann J; Al-Niaimi F; Cooper A; Ghura V
Br J Dermatol; 2016 Jan; 174(1):225-7. PubMed ID: 26286350
[No Abstract] [Full Text] [Related]
7. Syringotropic Melanoma Identified During Mohs Micrographic Surgery.
Donaldson MR; Morrell TJ; Weber LA
Dermatol Surg; 2021 Jun; 47(6):836-837. PubMed ID: 33165054
[No Abstract] [Full Text] [Related]
8. A Cross-Sectional Survey of Practice Patterns Among Mohs Micrographic Surgeons in the Assessment and Management of Perioperative Hypertension.
Ensslin CJ; Razavi CR; Lewin JM; Samie FH
Dermatol Surg; 2021 Jun; 47(6):829-831. PubMed ID: 33196589
[No Abstract] [Full Text] [Related]
9. Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining for atypical intraepidermal melanocytic proliferation.
Etzkorn JR; Jew OS; Shin TM; Sobanko JF; Neal DE; Miller CJ
J Am Acad Dermatol; 2018 Dec; 79(6):1109-1116.e1. PubMed ID: 30003986
[TBL] [Abstract][Full Text] [Related]
10. Mohs micrographic surgery for melanoma: A prospective multicenter study.
Ellison PM; Zitelli JA; Brodland DG
J Am Acad Dermatol; 2019 Sep; 81(3):767-774. PubMed ID: 31150700
[TBL] [Abstract][Full Text] [Related]
11. Mohs micrographic surgery with MART-1 immunostaining has durable low local recurrence rates for in situ and invasive melanomas.
Shin TM; Nugent S; Aizman L; Weiner DM; O'Malley V; Sobanko JF; Etzkorn JR; Chu EY; Elenitsas R; Giordano CN; Higgins Ii HW; Miller CJ
J Am Acad Dermatol; 2021 Jan; 84(1):196-198. PubMed ID: 32339704
[No Abstract] [Full Text] [Related]
12. Surgical Volume of Dermatologists Who Do Not Perform Mohs Micrographic Dermatologic Surgery: A Cross-Sectional Individual-Level Analysis Using Medicare Data.
Kantor J
Dermatol Surg; 2020 Jan; 46(1):1-6. PubMed ID: 31188146
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting.
Petty AJ; Ackerson B; Garza R; Peterson M; Liu B; Green C; Pavlis M
J Am Acad Dermatol; 2020 May; 82(5):1158-1165. PubMed ID: 31931085
[TBL] [Abstract][Full Text] [Related]
14. Comparison of staged excision and Mohs micrographic surgery with and without MART-1 immunostains for surgical treatment of melanoma of the head, neck, and special sites: A retrospective cohort study.
Wilson JG; German R; Hamann CR; Vidal NY; LeBoeuf M
J Am Acad Dermatol; 2021 Jan; 84(1):192-194. PubMed ID: 32348827
[No Abstract] [Full Text] [Related]
15. Trends in Medicare Billing Among Mohs Surgeons in the United States During 2012: A Retrospective Cohort Study.
Tsai S; Kooistra LJ; Conic RZ; Bordeaux JS
Dermatol Surg; 2019 Feb; 45(2):268-273. PubMed ID: 30199438
[TBL] [Abstract][Full Text] [Related]
16. Infection control practices in Mohs micrographic surgery: a U.K. national survey.
Chan BCY; Al-Niaimi F; Mallipeddi R
Br J Dermatol; 2017 Nov; 177(5):e204-e205. PubMed ID: 28407222
[No Abstract] [Full Text] [Related]
17. Changes in Use of Radiotherapy Among Dermatologists From 2013 to 2017.
Nguyen KD; Chen HW; Adamson AS
JAMA Dermatol; 2021 Mar; 157(3):322-325. PubMed ID: 33355610
[TBL] [Abstract][Full Text] [Related]
18. Melanoma Treated With Mohs Micrographic Surgery Using a Novel-Modified 15-Minute MART-1 Immunostain: Discussion of Technique and Experience.
Cheraghi N; Demer A; Meister A; Lee P
Dermatol Surg; 2021 Apr; 47(4):549-551. PubMed ID: 32483096
[No Abstract] [Full Text] [Related]
19. Comparison of MITF and Melan-A Immunohistochemistry During Mohs Surgery for Lentigo Maligna-Type Melanoma In Situ and Lentigo Maligna Melanoma.
Christensen KN; Hochwalt PC; Hocker TL; Roenigk RK; Brewer JD; Baum CL; Otley CC; Arpey CJ
Dermatol Surg; 2016 Feb; 42(2):167-75. PubMed ID: 26771682
[TBL] [Abstract][Full Text] [Related]
20. A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma.
Farberg AS; Rigel DS
J Am Acad Dermatol; 2016 Dec; 75(6):1193-1197.e1. PubMed ID: 27742167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
